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Aim: To assess associations between statin intensity and adherence, persistence and
discontinuation of statin therapy in Scotland.
Method: Retrospective cohort study, using linked electronic health records covering
a period from January 2009 to December 2016. The study cohort included adult
patients (≥18 years) newly initiating statins within Greater Glasgow and Clyde, Scot-
land. Study outcomes comprised adherence, discontinuation and persistence to treat-
ment, stratified by three exposure groups (high, moderate and low intensity).
Discontinuation and persistence were calculated using the refill-gap and anniversary
methods, respectively. Proportion of days covered (PDC) was used as a proxy for
adherence. Kaplan-Meier survival curves and Cox proportional hazard models were
used to evaluate discontinuation, and associations between adherence/persistence
and statin intensity were assessed using logistic regression.
Results: A total of 73 716 patients with a mean age of 61.4 ± 12.6 years were
included; the majority (88.3%) received moderate intensity statins. Discontinuation
rates differed between intensity levels, with high-intensity patients less likely to dis-
continue treatment compared to those on moderate intensity (prior cardiovascular
disease [CVD]: HR 0.43 [95% CI 0.34-0.55]; no prior CVD: 0.80 [0.74-0.86]). Persis-
tence declined over time, and high-intensity patients had the highest persistence
rates. Overall, 52.6% of patients were adherent to treatment (PDC ≥ 80%), but adher-
ence was considerably higher among high-intensity patients (63.7%).
Conclusion: High-intensity statins were associated with better persistence and
adherence to treatment, but overall long-term persistence and adherence remain a
challenge, particularly among patients without prior CVD. This needs addressing.
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1 | INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of death world-
wide.1 In Scotland, whilst the mortality from coronary heart disease
has been decreasing, treating and preventing CDV remains an impor-
tant priority in health care, particularly as its population is projected to
age considerably over the coming years, with an estimated 25% of the
population aged 65 years or older by 2041.2,3 In addition, there is a
high prevalence of risk factors associated with heart disease in Scot-
land, including smoking, poor diet and physical inactivity. Accordingly,
in 2015, 15% of adults aged 16 years or above had a cardiovascular
condition, which represents an estimated 670 000 people living with
CVD in Scotland. Both incidence and prevalence of CVD are higher
amongst men, the elderly and in deprived areas.2,4
CVD prevention is seen as a cost-effective strategy in many sce-
narios.4,5 Evidence from clinical trials and epidemiological studies has
shown a strong relationship between high low-density lipoprotein
cholesterol (LCL-C) levels and the incidence of CVD; lipid-lowering
therapy is associated with significant reductions in CVD morbidity
and mortality.6–9 Consequently, the use of statins, competitively
inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA)
reductase, is one of the cornerstones of CVD prevention.4,10,11
Recent evidence has supported the higher efficacy of high-
intensity statin therapy in comparison to low or moderate intensity,12
therefore the Scottish guidelines now recommend high-intensity
statin therapy, namely atorvastatin 80 mg, as the most clinically effec-
tive and cost-effective option for secondary prevention in patients
with established coronary vascular disease.4 Nevertheless, there are
concerns around the safety of high-intensity statins as high doses may
increase the incidence of statin-related side effects such as myopathy,
hepatotoxicity or diabetes,13–15 which in turn might impede patients'
adherence and persistence to treatment,16 and subsequently poten-
tially limit the clinical benefit of statins in reducing CVD.17–20 This is
particularly important given that long-term adherence to statin ther-
apy has already been shown to be far from optimal,21–25 and a signifi-
cant proportion of patients stop taking their statins within 2 years of
initiation.22,23 A wide range of factors, related to both the patient and
the healthcare provider, has been shown to impact adherence to long-
term treatment, for instance insufficient understanding of the disease,
concerns about side effects or inconsistent information received from
healthcare professionals.26 There is, however, limited and controver-
sial evidence to date with regard to the effect of statin intensity levels
on treatment adherence/persistence.27–29 A recent systematic review
of adherence and persistence with statins showed that only two of
the 84 studies included reported information on the statin intensity
regime and its correlation with adherence.30
Prescribing and dispensing data drawn from administrative
databases is particularly useful for conducting large observational
studies aimed at analysing drug utilisation rates, including
adherence/persistence to treatment.31,32 The National Health Service
(NHS) Scotland, which provides universal health care with no co-
payments for medicines for all residents in Scotland, offers a wide
array of routinely collected data suitable for drug utilisation research,
including prescribing and dispensing data.33
The aim of this study was to assess the association of statin ther-
apy intensity with adherence, persistence and discontinuation to/of
treatment, thereby covering two distinct phases of medication-taking
behaviour according to the Ascertaining Barriers for Compliance
(ABC) taxonomy: implementation and discontinuation.34 This informa-
tion is vital since there has been an increase in prescribing of high-
intensity statins in Scotland in recent years following advice from the
Scottish Government and Health Boards.4,35. The findings from this
study will be discussed with key stakeholder groups in Scotland to
instigate additional pertinent interventions if needed to further reduce
CVD rates.
2 | METHODS
2.1 | Study design and data sources
This retrospective longitudinal cohort study spanned from January
2009 to December 2016, using linked electronic health records for
patients registered within NHS Greater Glasgow & Clyde (NHS GGC),
the largest Health Board in Scotland. NHS GGC covers approximately
1.1 million people, or about 20% of the total Scottish population.36 It
comprises both urban and rural areas, as well as some of the most
deprived areas within Scotland. Although the share of elderly people
(over the age of 65 years) is slightly lower than the Scottish average,
NHS GGC is in general representative of Scotland overall, particularly
with regards to the prevalence of cardiovascular diseases.37,38
What is already known about this subject
• Long-term adherence to statin treatment is low and dis-
continuation rates are high.
• Guidelines for cardiovascular disease (CVD) prevention
increasingly recommend high-intensity statin therapy.
• As adverse events rates are likely higher with high-
intensity treatment, this could have a negative effect on
adherence rates, but evidence so far is scarce.
What this study adds
• Adherence to statin treatment was higher among patients
treated with high-intensity statins and discontinuation
rates were lower compared to moderate intensity.
• Patients with prior CVD (secondary prevention) had bet-
ter adherence that those without (primary prevention).
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New statin users were identified using the Prescribing Informa-
tion System (PIS), which covers all prescriptions dispensed within the
community (primary care) setting. PIS data contains information with
regards to both prescribing and dispensing (prescribed date and dis-
pensed month/year, prescribed and dispensed quantities, and dis-
pensed item name, strength and formulation), but due to the nature of
the database, PIS does not contain information about prescriptions
that have been issued but were not dispensed in a community phar-
macy.33 Data from PIS was linked to the Scottish Morbidity Records
Outpatient attendance (SMR00) and Inpatient and Day Care (SMR01)
datasets as well as to the Scottish death records using Community
Health Index (CHI) numbers. The CHI number is a unique patient iden-
tifier used throughout Scotland and incorporated into all NHS Scot-
land datasets.39
2.2 | Study cohort
The study population comprised all adult patients (≥18 years old) who
newly initiated statin therapy (atorvastatin, fluvastatin, pravastatin,
rosuvastatin or simvastatin) between January 2010 and December
2015 (cohort inclusion period); the date of first statin prescription was
the index date. New use was defined as having no prescription
records for any statin in the year prior to the index date (with the year
2009 used as a run-in period). Patients were excluded if they used a
statin as part of a fixed-dose combination. In addition, patients were
required to have at least 1 year follow-up time after the index date to
ensure sufficient time to evaluate study outcomes. Individual patients
were followed from the index date to either death or removal from a
Scottish General Practitioner register for other reasons (such as emi-
gration), with the date of emigration/death used as censor date where
applicable, or until the study end date (31 December 2016), which-
ever occurred first. Patients were not censored when being admitted
to a care home or hospital, as they are usually provided with medica-
tion through primary care or expected to bring their own chronic dis-
ease medication, respectively.
2.3 | Drug exposure
Detailed information about dispensed statin prescriptions was
extracted from PIS and included the nonproprietary name, drug for-
mulation, strength, prescription date and dispensed quantity. While
the dispensed quantity was used to calculate patients' days of supply,
the prescribing dates were used to estimate time periods between
prescriptions as these dates are more accurate than the available dis-
pensing dates (which default to the last day of each month). Statin
users were stratified into three exposure groups based on the first
statin received according to the current National Institute for Health
and Care Excellence (NICE) classifications (high, moderate and low
intensity) as detailed inTable 1.10 Only prescriptions for the first statin
intensity level issued to patients were taken into consideration when
calculating all outcome measures, with patients being allowed to
switch between statins within the same level of intensity (eg, simva-
statin 20 mg to atorvastatin 10 mg). Results therefore relate to the
level of statin used at the index date.
2.4 | Outcome measures
Medication-taking behaviour consists of three elements: initiation,
implementation, and discontinuation. While initiation and discontinua-
tion represent the start and end of drug treatment, respectively, the
process of implementation describes the extent to which a patient's
medication intake corresponds to what has been prescribed.34
Because of the nature of the data available, the outcome measures
used in this study covered the latter two elements and comprised
adherence, discontinuation and persistence to statin therapy, strati-
fied by the three exposure groups.
Discontinuation – to stop treatment – was calculated using the
refill-gap method, defined as a gap of more than 60 days without drug
supply following the assumed end of a prescription, that is, the last
day with assumed medication availability (grace period). Previous
oversupply of medicines (eg, due to early refills) was taken into
account.32 The period of 60 days was chosen based on observed pre-
scribing patterns and the recommendation to have a grace period of
at least the average prescription supply,40 which was 56 days in this
study. Patients were classified as having discontinued treatment when
switching to a different level of statin intensity. In addition, to assess
permanence of statin discontinuation, patients reinitiating treatment
after an initial discontinuation event were identified, and levels of
statin intensity prior and after this discontinuation were compared.
Persistence – being on treatment – was assessed at prespecified
points in time (6, 12, 24 and 36 months after treatment initiation)
using the anniversary method by assessing whether patients were in
possession of drug supply covering specific dates. This method aims
to account for both intermediary treatment interruptions and short-
term changes in intensity of therapy (eg, due to temporary shortages
of specific drugs).32 As patients were not censored when switching
between different statins or intensity levels, permanent switch of
intensity was classified as nonpersistence.
Proportion of days covered (PDC) was used as a proxy for adher-
ence – to take medication as prescribed. PDC was calculated by divid-
ing the total number of days covered by statin prescriptions by the
TABLE 1 Statin intensity levels according to the National
Institute for Health and Care Excellence
Statin
High
intensity
Moderate
intensity
Low
intensity
Atorvastatin 20-80 mg 10 mg …
Fluvastatin … 80 mg 20-40 mg
Lovastatin … 40 mg 10-20 mg
Pravastatin … 40-80 mg 10-20 mg
Rosuvastatin 20-40 mg 5-10 mg …
Simvastatin 80 mg 20-40 mg 10 mg
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total number of days in the follow-up period, capped at 100%. To cal-
culate days covered, dispensed quantities were used with an assumed
intake of one tablet/capsule a day. Applying the most commonly used
cut-off point, patients were classified as adherent when their PDC
was ≥80% and nonadherent with a PDC < 80%.31,41 In addition, to be
able to better distinguish between implementation and persistence,
the compliance rate (CR) was calculated: the number of days covered
by statin prescriptions (excluding the days' supply obtained at the last
dispensation) divided by the number of days in the period up to, but
not including, the last recorded prescription.41
2.5 | Covariables
Baseline patient characteristics were captured at index date and
included sex, age, first statin prescribed, year of statin initiation, depri-
vation, comorbidities and overall frailty. Deprivation was measured
using the Scottish Index of Multiple Deprivation (SIMD), ranked from
1 (most deprived) to 5 (least deprived).42 Comorbidities were assessed
by calculating a Charlson comorbidity score43 using International Clas-
sification of Diseases, 10th edition (ICD-10) codes, identified from
SMR00 and SMR01 records. The Charlson score is the most widely
used indicator of comorbidities and has been adapted by Quan et al
for use with ICD-10 codes.44 For the general measure of frailty, the
number of in-hospital days – regardless of cause – was counted dur-
ing the 2-year period prior to the index date, as recorded in SMR01.
2.6 | Statistical analysis
Descriptive statistics were used to assess baseline characteristics.
Continuous variables were summarised using means and standard var-
iation, while categorical variables were presented using absolute and
relative frequencies.
Kaplan-Meier survival curves were plotted to calculate the
median time to first discontinuation of statin use. Associations
between adherence/persistence to treatment and statin intensity
were assessed using logistic regression models; Cox proportional haz-
ard models were used to evaluate time to discontinuation. Moderate
intensity therapy was chosen as reference based on practical and clini-
cal deliberations. All findings were adjusted for baseline covariables,
using complete cases only (ie, excluding patients from the regression
analyses when data were missing).
All analyses were performed using the full patient cohort, as well
as stratified by whether a statin was prescribed for primary or second-
ary prevention. Secondary prevention was defined as having a diagno-
sis of myocardial infarction, angina, stroke or ischaemic heart disease
– recorded in SMR00/SMR01 – within the year preceding the index
date (ICD-10 codes I20-I24, I25.0, I25.1, I25.6, I25.8, I25.9, I51.6,
I51.7, I60-I64, G45.0-G45.3, G45.8, G45.9, H34.1). Sensitivity ana-
lyses were performed for discontinuation and persistence using alter-
native admissible intervals without drug supply (ie, supply gaps) of
30, 90, 120 and 180 days (grace periods).
All data analyses were conducted using R Studio, version 3.3.0.
For the extraction of PIS data, stored on an SQL server, the R package
Open Database Connectivity (RODBC) was used.45,46 Data were
anonymised, hosted and managed by the NHS GGC Safe Haven, and
their use was approved by the appropriate Local Privacy Advisory
Committee.
2.7 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked
to corresponding entries in http://www.guidetopharmacology.org,
the common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY.
3 | RESULTS
During the study period, a total of 212 953 patients received at least
one prescription for any statin. Of these, 139 237 patients were
excluded due to being below the age of 18 years when initiating treat-
ment, having been treated with statins during the run-in period,
having received fixed dose combinations including statins or not hav-
ing at least one full year of follow-up after the index date. This
resulted in 73 716 patients subsequently being included in the study
(Figure 1).
3.1 | Baseline characteristics
Of the 73 716 patients included in the study cohort, the majority
(88.4%) were initiated on moderate intensity therapy, followed by
9.7% on high intensity and 1.9% on low intensity. Simvastatin was the
most commonly prescribed statin, issued to 85.6% of all patients
newly initiating treatment and accounting for 95.0% and 79.8% of all
moderate and low-intensity therapy, respectively. In contrast, the vast
majority (98.1%) of patients who started high-intensity treatment
received atorvastatin. The mean age of all statin users was 61.4 years
(SD 12.6) and 39.5% were elderly (≥ 65 years), with 16.3% being
75 years of age or older. Slightly over half the patients (52.3%) were
male. The mean Charlson score was 0.77 (SD 1.32) and 45.2% of
patients had hospital admissions in the 2-year period prior to cohort
entry, with an average of 10.4 days (SD 26.1) of in-hospital stay.
There were, however, differences between the three intensity expo-
sure groups. With a mean age of 60.6 years (SD 12.7), patients on
high-intensity therapy were on average younger than those initiating
moderate (mean 61.4 years, SD 12.6) or low-intensity statins (mean
63.9 years, SD 13.3). High-intensity patients had, nevertheless, more
comorbidities, with higher mean Charlson scores, higher proportions
of patients with prior CVD (high intensity 25.6%, moderate intensity
13.4%, low intensity 4.8%) and higher proportions of patients with
recent admissions to hospital (high intensity 50.3%, moderate inten-
sity 44.7%, low intensity 38.9%). Details of baseline characteristics for
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the full cohort – overall as well as by statin intensity – can be found in
Supporting InformationTable S1.
When stratifying by primary/secondary prevention, patients with
prior CVD were older than those without (mean age 63.6 years
[SD 14.2] vs 61.0 years [SD 12.3]), predominantly male (58.9% vs
51.1% among patients without CVD) and had a higher mean Charlson
score (1.72 [SD 1.47] vs 0.55 [SD 1.17]). In addition, patients with
prior CVD had all recently been hospitalised, with an average of 16.5
(SD 30.9) in-hospital days, in contrast to only 39.5% of patients sub-
ject to primary prevention, with an average of 7.6 (SD 23.0) in-
hospital days. Differences between statin intensity levels were also
observed in both stratified cohorts (for details, seeTable 2).
3.2 | Discontinuation of treatment
During the study period, 46 730 patients (62.9%) discontinued statin
treatment and the median time to first discontinuation was 522 days
(95% confidence interval [CI] 510-535). Discontinuation rates as well
as time to discontinuation differed between intensity levels, however,
ranging from 50.9% with a median time to discontinuation of 911 days
(95% CI 843-1007) among patients treated with high-intensity statins
to 75.5% (median time to discontinuation 207 days (95% CI 168-244)
among low-intensity patients (see also Supporting Information Fig-
ures S1 and S2). Discontinuation also differed considerably between
patients with and without prior CVD, with overall rates of 48.0% and
65.4%, respectively. Similar to the overall cohort, discontinuation
rates in both these subgroups were lowest among patients treated
with high-intensity statins and highest among low-intensity statin
patients. Time to discontinuation varied widely between the different
patient groups, but was consistently longer for secondary prevention
(seeTable 3 and Figure 2 for details).
After adjusting for baseline patient characteristics (year of treat-
ment initiation, drug prescribed, sex, age category, deprivation (SIMD),
Charlson score [0 vs ≥1], prior CVD yes/no and hospitalisation
yes/no), patients on high-intensity statin therapy were less likely to
prematurely discontinue treatment than those on moderate intensity
therapy (Hazard Ratio [HR] 0.74, 95% CI 0.69-0.79). Although Hazard
Ratios differed considerably between patients with and without prior
CVD, stratified findings were in general similar to those observed in
the complete cohort. Compared to moderate intensity, high-intensity
statin patients were less likely to discontinue treatment regardless of
prior CVD status (with prior CVD: HR 0.43, 95% CI 0.34-0.55; with-
out prior CVD: HR 0.80, 95% CI 0.74-0.86) (Table 3).
3.3 | Reinitiation of treatment
Overall, 72.3% of patients reinitiated statin therapy after a first dis-
continuation event, the majority of which (72.7%) with the same statin
intensity that was used prior to treatment interruption, and 4.7% of
patients reduced and 23.2% increased statin intensity. The proportion
of patients changing intensity levels differed, however, between
patients with and without prior CVD (Figure 3).
3.4 | Persistence to treatment
In line with discontinuation rates, persistence to treatment also varied
significantly between statin intensity levels, with considerable
F IGURE 1 Study cohort identification flow chart
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differences between patients with and without prior CVD. Persistence
declined over time; nevertheless, patients subject to high-intensity
therapy had the highest persistence rates at all analysed time points.
Details are presented inTable 4.
In general, after adjusting for baseline characteristics, patients initi-
ating high-intensity statins were more likely to still be on treatment at
any point in time compared to patients initiating moderate intensity
therapy (6 months: Odds Ratio [OR] 1.48, 95% CI 1.30-1.68; 12 months:
OR 1.54, 95% CI 1.37-1.74; 24 months: OR 1.47, 95% CI 1.29-1.68).
Among patients with prior CVD, the ORs for being persistent with high-
intensity statins as compared to moderate intensity were 3.41 (95% CI
2.24-5.12) after 6 months, 2.94 (95% CI 1.97-4.34) after 12 months and
2.82 (95% CI 1.82-4.34) after 24 months. Although differing in magni-
tude, the findings paint a similar picture for patients without prior CVD.
Patients were more likely to be persistent with high-intensity statins
when compared to moderate intensity (6 months: OR 1.38, 95% CI
1.20-1.57; 12 months: OR 1.41, 95% CI 1.24-1.60; 24 months: OR
1.36, 95% CI 1.18-1.56) (seeTable 5 for details).
TABLE 2 Baseline characteristics of new statin users by intensity level and prior CVD status (type of prevention)
Prior CVD (secondary prevention) n = 10 632
(14.4%)
No prior CVD (primary prevention) n = 63 084
(85.6%)
Intensity, n (%) Intensity, n (%)
High 1834
(17.2)
Moderate 8730
(82.1)
Low 68
(0.6)
High 5329
(8.4)
Moderate 56 395
(89.4)
Low 1360
(2.2)
Sex, n (%)
Male 1196 (65.2) 5041 (57.7) 30 (44.1) 2931 (55.0) 28 728 (50.9) 608 (44.7)
Female 638 (34.8) 3689 (42.3) 38 (55.9) 2398 (45.0) 27 667 (49.1) 725 (53.3)
Age categories (years), n (%)
<55 685 (37.4) 2484 (28.5) 9 (13.2) 1619 (30.4) 17 737 (31.5) 326 (24.0)
55-64 531 (29.0) 2068 (23.7) 16 (23.5) 1587 (29.8) 17 112 (30.3) 374 (27.5)
65-74 333 (18.2) 1740 (19.9) 18 (26.5) 1330 (25.0) 13 340 (23.7) 368 (27.1)
75+ 285 (15.5) 2438 (27.9) 25 (36.8) 793 (14.9) 8206 (14.6) 292 (24.5)
Age (years), mean (SD) 59.7 (13.1) 64.4 (14.3) 68.3 (13.6) 60.9 (12.6) 60.9 (12.3) 63.7 (13.2)
Deprivation score (quintile), n (%)a
1 (most deprived) 754 (41.1) 3534 (40.5) 18 (26.5) 2034 (38.2) 22 616 (40.1) 406 (29.9)
2 300 (16.4) 1548 (17.7) 13 (19.1) 928 (17.4) 10 112 (17.9) 221 (16.3)
3 233 (12.7) 1192 (13.7) 13 (19.1) 740 (13.9) 7229 (12.8) 187 (13.8)
4 210 (11.5) 976 (11.2) 11 (16.2) 680 (12.8) 6671 (11.8) 227 (16.7)
5 (least deprived) 307 (16.7) 1366 (15.6) 11 (16.2) 869 (16.3) 9025 (16.0) 298 (21.9)
Calendar year of the first statin prescription, n (%)
2010 384 (20.9) 1566 (17.9) 17 (25.0) 748 (14.0) 11 513 (20.4) 315 (23.2)
2011 101 (5.5) 1753 (20.1) 16 (23.5) 396 (7.4) 9594 (17.0) 251 (18.5)
2012 140 (7.6) 1646 (18.9) 13 (19.1) 587 (11.0) 10 175 (18.0) 241 (17.7)
2013 251 (13.7) 1434 (16.4) 12 (17.6) 954 (17.9) 9515 (16.9) 214 (15.7)
2014 341 (18.6) 1332 (15.3) 5 (7.4) 1152 (21.6) 8370 (14.8) 210 (15.4)
2015 617 (33.6) 999 (11.4) 5 (7.4) 1492 (28.0) 7228 (12.8) 129 (9.5)
Charlson comorbidity score, n (%)b, c
0 90 (4.9) 677 (7.8) 9 (13.2) 2327 (43.7) 28 482 (50.5) 616 (45.3)
≥ 1 1744 (95.1) 8053 (92.2) 59 (86.8) 1143 (21.4) 11 571 (20.5) 353 (26.0)
Charlson comorbidity score, mean
(SD)2, 3
1.61 (1.31) 1.74 (1.49) 2.44 (2.15) 0.63 (1.25) 0.53 (1.15) 0.78 (1.44)
Hospitalization (yes), n (%)d 1834 (100) 8730 (100) 68 (100) 1768 (33.2) 20 402 (36.2) 487 (35.8)
General patient fragility, mean (SD)4 12.3 (24.1) 17.3 (32.1) 24.6 (34.8) 6.8 (17.8) 7.6 (23.5) 8.5 (21.5)
Abbreviations: CVD, cardiovascular disease.
a1.3% (n = 987) of missing data: secondary prevention n = 146 (1.4%), primary prevention n = 841 (1.3%).
bBased on all ICD codes recorded in hospital records during the 2-year period preceding the index date.
c25.2% (n = 18,592) of missing data: secondary prevention n = 0 (0%), primary prevention n = 18,592 (29.5%).
dIn-hospital days, assessed during the 2-year period preceding the index date.
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TABLE 3 Crude discontinuation rates, time to discontinuation and adjusted HRs by intensity level and prior CVD status (type of prevention)
Crude discontinuation
rate (%)a
Median time to first discontinuation
(95% CI) (days)b Hazard Ratio (95% CI), adjustedc
All patients 62.9 522 (510-535)
Low intensity 75.5 207 (168-244) 1.56 (1.45-1.69)
Moderate intensity 63.9 504 (493-517) 1
High intensity 50.9 911 (843-1007) 0.74 (0.69-0.79)
Prior CVD (secondary prevention) 48.0 1232 (1168-1296)
Low intensity 58.8 209 (87-NR) 1.85 (1.30-2.63)
Moderate intensity 50.4 1,126 (1064-1201) 1
High intensity 36.3 2,028 (1676-NR) 0.43 (0.34-0.55)
No prior CVD (primary prevention) 65.4 440 (429-450)
Low intensity 76.3 203 (168-244) 1.55 (1.43-1.67)
Moderate intensity 66.0 435 (424-448) 1
High intensity 55.9 615 (561-705) 0.80 (0.74-0.86)
Abbreviations: CI, confidence interval; CVD, cardiovascular disease; NR, not reached.
aRefill-gap method, admissible gap 60 days.
bKaplan-Meier survival, unadjusted.
cReference category is moderate intensity, adjusted for baseline variables: year of treatment initiation, drug prescribed, sex, age category, deprivation
(SIMD), Charlson score (0 vs ≥1), prior CVD yes/no, hospitalisation yes/no.
F IGURE 2 Kaplan-Meier curves of
time to first treatment discontinuation by
CVD status (type of prevention)
F IGURE 3 Discontinuation and reinitiation of treatment by CVD status (type of prevention)
REZENDE MACEDO DO NASCIMENTO ET AL. 7
3.5 | Adherence to treatment
Only patients who had at least two dispensing records for the same
statin intensity were included in the adherence analysis, totalling
66 248 patients (89.9% of all new statin users during the study
period). Based on PDC, the overall adherence rate for the full cohort
was 52.6%, but adherence to treatment was significantly higher
among high-intensity statin users, with 63.7% classified as adherent in
contrast to 51.6% and 40.5% among moderate- and low-intensity
users, respectively. There were also differences in adherence between
patients with and without prior CVD, with higher adherence rates
among patients subject to secondary prevention at all levels of statin
intensity (Table 6).
When using the CR instead of the PDC, the overall adherence
rate was considerably higher at 69.3% and differences between inten-
sity levels were less pronounced, with between 68.5% and 76.1% of
patients considered adherent to treatment. Again, patients with prior
CVD had higher adherence rates at all levels of statin intensity (for
details seeTable 7).
After adjusting for baseline characteristics, compared to moderate
intensity, patients on high-intensity statin therapy in general were
more likely to be adherent to treatment, regardless of outcome
TABLE 4 Crude persistence rates at specific points in time since treatment initiation by intensity level and prior CVD status (type of
prevention)
Persistence rate (%)a,b 6 months 12 months 24 months 36 months
All patients 76.8 69.9 63.7 59.2
Low intensity 62.7 53.1 43.4 36.2
Moderate intensity 76.7 69.8 63.8 59.4
High intensity 80.1 74.7 68.0 63.3
Prior CVD (secondary prevention) 88.6 81.6 74.0 68.2
Low intensity 59.1 50.8 42.6 39.6
Moderate intensity 88.7 81.0 73.5 67.6
High intensity 89.7 85.5 78.0 73.5
No prior CVD (primary prevention) 74.8 68.0 62.1 57.8
Low intensity 62.9 53.2 43.4 36.1
Moderate intensity 74.9 68.1 62.3 58.2
High intensity 76.8 71.0 64.8 60.0
Abbreviations: CVD, cardiovascular disease.
aAnniversary method, admissible gap 60 days.
bDenominators are patients with sufficient follow-up time within a specific category.
TABLE 5 Adjusted ORs for persistence at specific points in time since treatment initiation by intensity level and prior CVD status (type of
prevention)
OR (95% CI), adjusteda,b 6 months 12 months 24 months
All patients
Low intensity 0.45 (0.39-0.52) 0.45 (0.40-0.52) 0.40 (0.34-0.46)
Moderate intensity 1 1 1
High intensity 1.48 (1.30-1.68) 1.54 (1.37-1.74) 1.47 (1.29-1.68)
Prior CVD (secondary prevention)
Low intensity 0.17 (0.10-0.32) 0.22 (0.12-0.39) 0.23 (0.12-0.43)
Moderate intensity 1 1 1
High intensity 3.41 (2.24-5.12) 2.94 (1.97-4.34) 2.82 (1.82-4.34)
No prior CVD (primary prevention)
Low intensity 0.47 (0.41-0.54) 0.47 (0.41-0.54) 0.41 (0.35-0.48)
Moderate intensity 1 1 1
High intensity 1.38 (1.20-1.57) 1.41 (1.24-1.60) 1.36 (1.18-1.56)
Abbreviations: CI, confidence interval; CVD, cardiovascular disease; OR, Odds Ratio.
aAnniversary method, admissible gap 60 days.
bReference category is moderate intensity, adjusted for baseline variables: year of treatment initiation, drug prescribed, sex, age category, deprivation
(SIMD), Charlson score (0 vs ≥1), prior CVD yes/no, hospitalisation yes/no.
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measurement used (PDC: OR 1.54, 95% CI 1.37-1.74; CR: OR 1.27,
95% CI 1.11-1.45). Adherence was similar to the overall results when
looking only at patients without prior CVD/primary prevention (PDC:
OR 1.39, 95% CI 1.22-1.58; CR: 1.22, 95% CI 1.06-1.41), but was con-
siderably higher among patients with prior CVD/secondary preven-
tion (PDC: OR 3.06, 95% CI 2.10-4.46; CR: 1.98, 95% CI 1.25-3.08)
(Tables 6 and 7).
3.6 | Sensitivity analyses
Results from the sensitivity analyses were consistent with the main
analysis, although changing the length of permissible gaps had an
impact on absolute numbers of patients discontinuing treatment, as
well as on the median time to treatment discontinuation. When all-
owing for a short gap of 30 days, the overall proportion of patients
discontinuing treatment increased to 75.0%, with a median time to
discontinuation of 256 days (95% CI 251-261). In contrast, extending
the admissible gap to 90, 120 and 180 days resulted in decreased dis-
continuation rates of 56.0% (median time to discontinuation 798 days,
95% CI 778-818), 52.1% (median time to discontinuation 1029 days,
95% CI 1002-1052) and 47.5% (median time to discontinuation
1409 days, 95% CI 1372-1445), respectively. In line with these find-
ings, overall persistence rates decreased when shortening the admissi-
ble gap and increased when expanding it. Overall trends and
differences between patients with or without prior CVD, or between
TABLE 6 Crude adherence rates, median PDC and adjusted ORs by intensity level and prior CVD status (type of prevention)
PDC ≥ 80% Median PDC (IQR) OR (95% CI), adjusteda
All patients 52.6 83.3 (36.7-99.9)
Low intensity 40.5 58.2 (16.8-96.8) 0.58 (0.50-0.68)
Moderate intensity 51.6 82.0 (35.6-99.5) 1
High intensity 63.7 93.4 (59.0-100.0) 1.54 (1.37-1.74)
Prior CVD (secondary
prevention)
64.7 94.3 (58.4-100.0)
Low intensity 58.3 97.4 (24.4-100.0) 0.78 (0.41-1.50)
Moderate intensity 62.7 93.1 (54.1-100.0) 1
High intensity 74.1 98.7 (78.7-100.0) 3.06 (2.10-4.46)
No prior CVD (primary prevention) 50.4 80.5 (34.0-99.1)
Low intensity 39.6 56.4 (16.4-96.3) 0.57 (0.48-0.67)
Moderate intensity 49.7 79.7 (33.3-98.9) 1
High intensity 59.8 90.1 (51.7-100.0) 1.39 (1.22-1.58)
Abbreviations: CI, confidence interval; CVD, cardiovascular disease; IQR, inter-quartile range; OR, Odds Ratio; PDC, proportion of days covered.
aReference category is moderate intensity, adjusted for baseline variables: year of treatment initiation, drug prescribed, sex, age category, deprivation
(SIMD), Charlson score (0 vs ≥1), prior CVD yes/no, hospitalisation yes/no.
TABLE 7 Crude adherence rates, median CR and adjusted OR by intensity level and prior CVD status (type of prevention)
CR ≥ 80% Median CR (IQR) OR (95% CI), adjusteda
All patients 69.3 93.2 (72.9-101.1)
Low intensity 72.5 94.9 (76.9-103.2) 1.19 (1.00-1.41)
Moderate intensity 68.5 92.8 (71.9-101.0) 1
High intensity 76.1 96.0 (81.3-102.1) 1.27 (1.11-1.45)
Prior CVD (secondary prevention) 82.5 97.6 (87.6-103.1)
Low intensity 85.4 99.7 (94.4-108.3) 1.19 (0.53-3.08)
Moderate intensity 81.9 97.4 (87.0-103.0) 1
High intensity 85.1 98.3 (89.8-103.2) 1.98 (1.25-3.08)
No prior CVD (primary prevention) 66.9 92.0 (70.1-100.7)
Low intensity 71.9 94.5 (75.9-103.0) 1.19 (1.00-1.42)
Moderate intensity 66.3 91.7 (69.4-100.6) 1
High intensity 72.7 94.6 (77.4-101.7) 1.23 (1.06-1.41)
Abbreviations: CI, confidence interval; CR, compliance rate; CVD, cardiovascular disease; IQR, inter-quartile range; OR, Odds Ratio.
aReference category is moderate intensity, adjusted for baseline variables: year of treatment initiation, drug prescribed, sex, age category, deprivation
(SIMD), Charlson score (0 vs ≥1), prior CVD yes/no, hospitalisation yes/no.
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different levels of statin intensity, were not affected (detailed results
not shown).
4 | DISCUSSION
This longitudinal cohort study assessed the impact of statin intensity
on all medication-taking behaviours (adherence, persistence and dis-
continuation) over a 7-year period. Unexpectedly, compared to mod-
erate statin intensity, high-intensity statin therapy was associated
with better adherence and persistence to treatment, and lower dis-
continuation rates. Nevertheless, in line with other published studies
which evaluated discontinuation of and persistence to statins,21–25,30
discontinuation rates were high overall, persistence to treatment
decreased over time, and adherence was in general suboptimal. How-
ever, none of these studies assessed the impact of statin intensity.
Although differences between intensity levels have previously
been reported, albeit to varying degrees depending on the specific
population studied (eg, a study conducted in Israel found adherence
to be lowest among high-intensity statin users,27 while a Japanese
study observed both higher and lower adherence with high-intensity
statin therapy in comparison to moderate intensity depending on the
database used),28 this is, to the best of our knowledge, the first study
to comprehensively analyse all aspects of medication-taking behav-
iour (ie, discontinuation, persistence and adherence) with regard to
statin therapy, taking into consideration both the level of statin inten-
sity and whether patients have been subject to primary or secondary
prevention.
Discontinuation was consistently lowest among high-intensity
patients in the full cohort as well as in the subgroups when stratifying
by primary/secondary prevention. This is encouraging given the initial
concerns that discontinuation rates may be higher among high-
intensity patients due to potentially increased side effects with
increased dosage. Interestingly, atorvastatin, which accounted for the
vast majority of high-intensity therapy in our study, has recently been
associated with lower odds of discontinuing statin treatment than
simvastatin in a study conducted in Australia.25 This was despite ator-
vastatin having been linked with higher levels of adverse events in
comparison to simvastatin.47 Differences in discontinuation rates
were still observed when adjusting for patients' baseline characteris-
tics, potentially indicating that higher intensity statins are either not
associated with a significantly higher occurrence of side effects; or
that patients are more tolerant towards minor side effects than antici-
pated if there is sufficient motivation to continue treatment. Unfortu-
nately, adverse events data were not available to confirm these
hypotheses. Bearing in mind that a considerable proportion of
patients (72.3%) reinitiated treatment after a first discontinuation
event, the latter might at least partially explain the results, especially
when considering that patients being treated with high-intensity sta-
tins will have a higher risk of serious cardiovascular events and thus
might be more receptive to being prescribed a statin, while simulta-
neously prescribers might be more vigilant with continuing treatment
in a high-risk patient group.
Persistence in all treatment groups decreased over time. While
76.8% of all patients were still on treatment after 6 months, this
decreased to 69.9% after 1 year, albeit with significant differences
between intensity levels, with persistence consistently highest among
high-intensity patients. Similarly, adherence to statin therapy was
poor overall, with only just over half of all patients (52.6%) categorised
as adherent during the study period; again, high intensity patients
generally displayed better adherence. When assessing adherence
using CRs instead of the frequently applied PDC, a noticeably higher
percentage of patients (overall 69.3%) was considered adherent to
treatment. Differences between these two outcome measures were
particularly marked within the low-intensity treatment groups,
highlighting the potentially substantial impact of early treatment dis-
continuation on measurements of adherence. Remarkably, adherence
remained higher among patients treated with high-intensity statins
even when using CRs. As in previous studies, both persistence and
adherence to treatment (regardless of measurement used) were
higher among patients with a recent previous cardiovascular event
such as a myocardial infarction or stroke.21,22,25,28,48
Low adherence to long-term treatment may be related to a range
of parameters involving prescribers, patients, or both, and it is con-
ceivable that factors such as insufficient explanation about the treat-
ment and the impact of noncompliance, an underestimation of disease
risks or the probability of drug-related adverse events (which have all
been shown to influence adherence to medication20,26,49) are distrib-
uted differently between distinct patient groups, with subsequent
effects on outcomes. These factors, however, could not be analysed
in this study. Consequently, the reasons for the observed substantial
differences in treatment adherence among the study participants
remain unclear and need to be investigated further to enhance future
adherence rates in Scotland.
Keeping the findings of not only this study but also results from
other studies in mind, it seems pertinent to consider how best to
increase adherence to statin therapy, as statins are a proven and cost-
effective means of preventing cardiovascular diseases, which are,
despite recent improvements, still a major cause of death and disabil-
ity in Scotland.2 Interventions to improve adherence that have been
suggested include interactive voice response reminders, regular medi-
cation reviews by community pharmacists, and repeat disease
counselling through nurses or physicians.50 Several studies26,49,51
have highlighted that the patients who were most satisfied with their
physician's explanations were more likely to remain current medicines
users and to have better adherence. With pharmacists increasingly
being introduced into GP practices in Scotland,52 there is scope to
explore options for improving the dialogue between patients and
healthcare professionals, and to potentially implement other interven-
tions tailored to patients that could improve adherence to statins -
such as providing verbal and written information about the disease
and/or the treatment, adapting treatment regimens or using dispens-
ing support tools such as dosette boxes, depending on context and
reasons for nonadherence to therapy.53 Most importantly, shared
decisions about the initiation of treatment, discussing the potential
risks and benefits of statin therapy, and shared management plans are
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essential to improve adherence rates and quality of medicines
use.20,26 We will be discussing the implications of our findings with
key stakeholders in Scotland as a basis for debating possible future
interventions that could be instigated to improve prescribing and
adherence rates.
4.1 | Strengths and limitations
This is a population-based study assessing the association of statin
intensity with the entire medication-taking behaviour process, hence
providing unprecedented insight into adherence to statin treatment.
Considering that access to health care is universal and electronic
health records cover the entire population, some confounding
factors present in other settings, such as missing out on sections of
the population based on incomplete health insurance coverage or
inaccessibility of treatment due to copayments, are not present in
Scotland. Furthermore, PIS and SMR01 have previously been used for
research, and data validity and accuracy have been established.54
Nevertheless, this study has several limitations. First, study data
were obtained from NHS Scotland information systems, which have
been implemented for administrative purposes; hence, not all desir-
able data were available. Details about diagnoses and the indication
for drug treatment, for instance, are not available in PIS. Conse-
quently, the indication for the use of statins (ie, primary or secondary
prevention) was estimated based on hospital records, potentially
affecting the accuracy of findings based on stratification by the pres-
ence or absence of prior CVD. In addition, due to the lack of primary
care data, the Charlson Comorbidity Index was calculated using hospi-
tal discharge records and since some comorbidities might not have
been captured, Charlson scores might have been underestimated.
Data regarding the number of medications taken by patients, occa-
sionally used as a proxy for comorbidities but also an important factor
when assessing adherence in itself, were also not available for analy-
sis, with potential implications for the interpretation of results. Fur-
thermore, data related to clinical or behavioural factors such as lipid
control and other potentially confounding lifestyle variables (including
smoking habits, diet and physical activity) were unavailable. Conse-
quently, reasons for discontinuation of treatment (which could have
been based on a decision made by the prescriber rather than the
patient, particularly among low-risk patients being treated with low or
moderate intensity statins) were unknown. Second, the lack of
standardised definitions and methods for measuring adherence, dis-
continuation and persistence could hamper comparison of findings
across studies, but this is a well-recognised issue in drug utilisation
research.34,54 To accommodate the range of admissible gaps used in
other studies, we conducted sensitivity analyses. Apart from changes
in absolute numbers of patients discontinuing treatment, overall
trends and differences between patients with and without prior CVD,
or between levels of statin intensity, were not affected. Furthermore,
based on applied definitions and calculations, adherence for individual
patients could have been underestimated/discontinuation might have
been overestimated if they intermittently received statin prescriptions
for a different intensity, but the impact on overall findings is likely to
be small due to small numbers of observed instances. Finally, an
important limitation is the underlying assumption that all dispensed
medicines were taken by patients, which is not always the case.
Although findings could have been impacted if patients continued to
fill in prescriptions despite not actually taking the drugs, this limitation
is difficult to address, especially considering the size of the study
cohort. As with all observational research, unmeasured confounding
cannot be ruled out.
5 | CONCLUSIONS
The study findings indicate higher long-term persistence and adher-
ence among high-intensity statin users compared to moderate inten-
sity, thus not supporting our initial concerns that high-intensity statin
therapy might impede patients' persistence and adherence due to
higher risks of side effects. However, the study findings reinforce cur-
rent beliefs that long-term persistence and adherence to treatment
with statins remain a challenge in the prevention of CVD, as this
potentially leads to suboptimal treatment outcomes. Further research,
potentially analysing laboratory data in combination with adverse
events, is urgently needed to address these issues. Furthermore, steps
need to be undertaken to encourage persistence and adherence in
Scotland, particularly among patients without prior CVD where statins
have been prescribed. We will be following up on this with key stake-
holders to plan next steps given the continual high rates of CVD in
Scotland.
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